Nanomerics today announced end of dosing with all volunteers completing the full schedule and without moderate or severe adverse events...

Nanomerics Ltd., a private speciality pharmaceutical company today announced that its Chief Scientific Officer, Professor Ijeoma F....

Following approval in November 2024 from the UK Medicinal and Healthcare Products Regulatory Agency (MHRA), dosing of the first...

London, United Kingdom, November 18th, 2024.  Nanomerics Ltd ., a private speciality pharmaceutical company announced that it had...

Nanomerics CSO Prof IF Uchegbu chats to Jim Al-Khalili about her life - scientific and otherwise. The program is available on BBC Sounds...

In collaboration with the Royal Society of Chemistry (RSC), Nanomerics recently hosted an industry site visit for the participants of the...

Nanomerics proudly announces its continuous participation as an industry partner in the Royal Society of Chemistry's (RSC) Broadening...

Manchester, United Kingdom May 22nd, 2024.  Nanomerics Ltd., a private speciality pharmaceutical company today announced that Professor...

London, United Kingdom May 6th, 2024.  Nanomerics Ltd ., a private speciality pharmaceutical company today announced that it had been...

London, United Kingdom April 24th 2024. Nanomerics Ltd., a private speciality pharmaceutical company today announced that Professor...

Nanomerics Ltd., a private speciality pharmaceutical company today announced that the Company had been granted patent protection in...

Today Nanomerics is pleased to announce that the publication (SARS-CoV-2 inhibition using a mucoadhesive, amphiphilic chitosan that may...

Nanomerics CSO Ijeoma Uchegbu has been appointed to the board of Wellcome Ijeoma Uchegbu appointed to Wellcome board | News | Wellcome

Nanomerics Ltd., a world leader in molecular engineered delivery technologies, today announced the Company had been granted patent...

Today the UK Academy of Medical Sciences announced the election of 50 new biomedical health scientists to its influential fellowship;...

Nanomerics Ltd., a world leader in molecular engineered delivery technologies, today announced that the Company had received its first...

Nanomerics Molecular Mask MM019 inhibits SARS-CoV-2 replication in ex-vivo human airway epithelial air liquid interface cultures. Today...

Today Nanomerics received supportive pIND guidance from the US FDA on the development of its asset - NM134. NM134 is indicated for the...